Arterial stiffness is a risk factor for cardiovascular disease. Transforming growth factor b1 is a pleiotropic cytokine, with many functions, including influence on the vascular wall (e.g., on angiogenesis, endothelial cells and the extracellular matrix). We investigated five functional polymorphisms in the transforming growth factor b1 gene (À800 G/A, À509 C/T, codon 10 Leu/Pro, codon 25 Arg/Pro and codon 263 Thr/Ile) in relation to arterial stiffness in a population-based study. A total of 3863 participants of the Rotterdam Study, a prospective population-based study, were included in the current study. The relations of the genotypes and haplotypes with arterial stiffness (pulse wave velocity (PWV), distensibility coefficient (DC) and pulse pressure (PP)) were studied using analyses of variance and linear regression. The analyses were adjusted for age, sex, mean arterial pressure, heart rate, conventional cardiovascular risk factors and measures of atherosclerosis. There were no associations between PWV and À800 G/A (P ¼ 0.56), À509 C/T (P ¼ 0.29), codon 10 (P ¼ 0.98) and, codon 25 (P ¼ 0.28). These polymorphisms were not associated with the DC or with PP. The haplotype-based analyses yielded similar results. The results of this study show that the TGF-b1 -800 G/A, À509 C/T, codon 10 Leu/Pro and codon 25 Arg/Pro polymorphisms are not associated with arterial stiffness.
Introduction
Arterial stiffness increases with age. Increased arterial stiffness is also associated with hypertension, diabetes mellitus (DM), end-stage renal disease and atherosclerosis. [1] [2] [3] [4] [5] [6] Recently, it has also been shown to be associated with increased risk of cardiovascular disease. [7] [8] [9] The extent of the increase in stiffness may depend on various factors; it is likely that genetic variations play a role. Indeed, a recent study described heritability estimates of arterial stiffness (varying from 0.26 to 0.36). 10 Transforming growth factor b (TGF-b) is a pleiotropic cytokine. In man, three isoforms (with largely similar functions) exist, of which TGF-b1 is the most common. 11 Its effects include influence on T-cells, on the release of (other) cytokines and fibroblast growth factors, but it also exerts influence on the vascular wall, for example in angiogenesis, on endothelial cells and on modulation of the extracellular matrix. [12] [13] [14] [15] [16] [17] TGF-b also regulates (vascular) smooth muscle cell differentiation. [18] [19] [20] [21] Robertson et al. 13 described that disruption of TGF-b signaling in mice led to decreased collagen in plaques. Others also found TGF-b to be associated with collagen upregulation in the vascular wall. 15, 18 Also Mallat et al.
14 described TGF-b as a profibrotic cytokine. Increased TGF-b has also been implicated in the fibrosclerotic process in varicose vessel walls. 22 Variations in bioavailability of TGF-b levels may therefore influence arterial stiffness and the TGF-b gene is a candidate gene for further study of variation in arterial stiffness.
The TGF-b1 gene (23.5 kb) is located on chromosome 19q13.2. There are several commonly known (potentially) functional polymorphisms in this gene. Cambien et al. 23 described the À988 C/A, À800 G/A, À509 C/T polymorphisms (promoter region); a Cinsertion at position þ 72 (non-translated region); and in addition codons 10 Leu/Pro (c10) and 25 Arg/ Pro (c25) (signal peptide sequence) and 263 Thr/Ile (c263) (precursor part of the protein). Of these, þ 72 was in almost complete linkage disequilibrium with c25, whereas -988 C/A was extremely rare. 23 Grainger et al. 24 described the -509 C/T polymorphism to be associated with levels of TGF-b1.
The TGF-b1 -800 G/A and -509 C/T polymorphisms are located in the promoter region; the full extent of their effect is still unknown, but owing to their location, they are considered possible modulators of expression of the TGF-b gene and levels. [23] [24] [25] The c10 and c25 polymorphisms are located in the signal peptide sequence, which is involved in export of synthesized proteins across membranes of the endoplasmatic reticulum, thereby possibly influencing TGF-b levels. 23 The c10 and c25 polymorphisms are also located at potentially important positions that influence activation of the TGF-b protein. 25 To the best of our knowledge, these (potentially) functional polymorphisms have not been investigated in association with arterial stiffness before. We studied the association of the TGF-b1 -800 G/A, À509 C/T, c10, c25 and c263 polymorphisms and arterial stiffness in a large population-based study.
Materials and methods
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants of 55 years and older. Its general aims are to investigate determinants of chronic diseases. 26 During the first phase of this study (1990) (1991) (1992) (1993) , all inhabitants of a Rotterdam suburban area (Ommoord) aged 55 years and over were invited to participate in this study. The response rate was 78%. The third examination phase took place from 1997 to 1999, during which measures of arterial stiffness were performed. Approval of the Medical Ethics Committee of the Erasmus University Rotterdam was obtained for the Rotterdam Study. From all participants written informed consent was acquired. A more in depth description of the Rotterdam Study was published previously. 26 
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to standard procedures. Genomic DNA 1-2 ng was dispensed into 384-well plates using a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, Mountain View, CA, USA). Genotypes were determined using the Taqman allelic discrimination assay. The assayby-design service (www.appliedbiosystems.com) was used to set up assays for the 800 G/A an assay was set up using primer express 2.0 software (Applied Biosystems Inc., Foster City, CA, USA). The assays-by-design consisted of 5 ng of genomic DNA in a 2 ml volume and the following reagents: FAM and VIC probes (400 nM), primers (1.8 mM), 2 Â Taqman PCR master mix (ABgene). The assay for codon 25 consisted of 5 ng of genomic DNA in a 4 ml volume and the following reagents: FAM probes (250 nM), TET probe (500 nM), primers (300 nM), 2 Â Taqman PCR master mix (ABgene). Reagents were dispensed in a 384-well plate using the Deerac Equator NS808 (Deerac Fluidics, Dublin, Ireland). PCR cycling reaction were performed in 384-well PCR plates in an ABI 9700 PCR system (Applied Biosystems Inc., Foster City, CA, USA) and consisted of initial denaturation for 15 min at 951C, and 40 cycles with denaturation of 15 s at 951C and annealing and extension for 60 s at 601C. Results were analyzed by the ABI Taqman 7900HT using the sequence detection system 2.22 software (Applied Biosystems Inc., Foster City, CA, USA). To confirm the accuracy of genotyping results, 332 (5%) randomly selected samples were regenotyped with the same method. All polymorphisms had an error rate lower than 1%. The polymorphisms were selected based on (potential) functionality (-800 G/A and -509 C/T located in promotor; codons 10, 25 and 263 resulting in an amino-acid change) and literature, describing previous research on these polymorphisms and cardiovascular disease.
Haplotyping
Haplotypes were reconstructed using PHASE software (http://archimedes.well.ox.ac.uk). Genotype data of the four TGF-b1 polymorphisms in HardyWeinberg equilibrium (HWE) (À800 G/A, -509 C/T, codon 10 Leu/Pro and, codon 25 Arg/Pro) enabled us to distinguish the four most common haplotypes. They were coded as one to four in order of decreasing frequency in the population (coding from À800 G/A, -509 C/T, c10 Leu/Pro, c25 Arg/ Pro: (Figures 1 and 2 ).
Arterial stiffness
In this study, three measures of arterial stiffness were used: the carotid-femoral pulse wave velocity (PWV, or aortic stiffness) as a measure of aortic stiffness, the distensibility coefficient (DC, or carotid stiffness) of the common carotid artery as a measure of common carotid arterial stiffness and, in addition, pulse pressure (PP) was assessed as an indicator of arterial stiffness. All measures were obtained on the same day, during the same session, during the third follow-up examination.
Carotid-femoral PWV (m/s) was measured using an automatic device (Complior, Colson) and was calculated as the ratio between the distance travelled by the pulse wave and the foot-to-foot time delay.
Common carotid artery distensibility was assessed by measuring the vessel wall motion of the right common carotid artery using a duplex scanner (ATL Ultramark IV, operating frequency 7.5 MHz) connected to a vessel wall movement detector system. 27, 28 The cross-sectional arterial wall DC (1/MPa) was calculated as a measure of arterial stiffness. 29 A decreased DC implies increased carotid stiffness.
PP (mm Hg) was defined as the difference between systolic and diastolic blood pressure, using the mean systolic and diastolic blood pressure of two measurements obtained by measuring blood pressure on the right arm using a random-zero sphygmomanometer.
Details on all measures of stiffness, have been described previously. 6, 9 Clinical characteristics We collected information on cardiovascular risk factors during the third follow-up examination. During the home interview information was collected on medication use and smoking habits. Smoking was classified as never, former or current smoking. At the research centre, blood pressure was measured twice on the right arm using a randomzero sphygmomanometer. The average of the two blood pressure values was used in the analyses. Hypertension was defined as having a systolic blood pressure of X160 mm Hg and/or diastolic blood pressure of X100 mm Hg and/or blood pressure lowering medication with an indication for hypertension. Height and weight were measured and body mass index (kg/m 2 ) (BMI) was calculated. Serum total cholesterol and high-density lipoprotein (HDL) cholesterol values were determined by an automated enzymatic procedure (Boehringer Mannheim System). DM was defined as use of anti-diabetic medication and/or a fasting serum glucose level of equal to or above 7.0 mmol/l. 30 Evaluation of the atherosclerotic status of participants was accomplished using ultrasonography (carotid intima-media thickness (IMT)) and radiography (aorta calcification); these methods have been extensively described previously.
31,32
Population for analysis A total of 4024 subjects underwent the physical examination of the third phase and PWV was measured in 3550 subjects; 69 subjects (1.9%) were excluded from the analyses because of poor quality of the PWV recordings, leaving 3481 subjects, whereas common carotid distensibility was measured in 3098 subjects. Information on the -800 G/A polymorphism and PWV measurements were available for 3221 subjects and on distensibility for 2845 subjects. For the -509 C/T polymorphism the corresponding numbers were 3174 and 2804 subjects. For codon 10, codon 25 and codon 263 corresponding numbers were 3113 and 2750 subjects. Data on PP was available for 3847 genotyped subjects. A total of 3863 subjects were successfully genotyped for at least one of the polymorphisms and information was available on either PWV, DC or PP. Of these, 3740 subjects were successfully haplotyped. Missing information on measures of arterial stiffness was almost entirely owing to logistic reasons.
Statistical analyses
Chi-square tests were performed to test for deviations from HWE. Missing data in clinical characteristics were imputed using ExpectationMaximization algorithms available in SPSS. The associations between the genotypes and haplotypes and arterial stiffness were investigated using analyses of variance and linear regression. The haplotype analyses were allele-based: each haplotype allele (as opposed to a haplotype allele pair) is considered and analyzed separately, using the outcomes and characteristics of the subject carrying that allele. The most common haplotype allele is the reference (i.e., haplotype 1). All analyses were adjusted for age and sex and (if applicable) additionally for mean arterial pressure (MAP), heart rate, BMI, HDL and total cholesterol levels, smoking, DM and measures of atherosclerosis (carotid IMT and aorta calcification). A P-value of 0.05 and smaller was considered significant in all analyses. The statistical analyses were performed using SPSS version 11.0.1 for MS-Windows.
Results
Genotype and allele proportions were in HWE, except for c263 (P ¼ 0.00078). Therefore, this polymorphism genotype was not included in the analyses. Haplotypes are shown in Figures 1 and  2 . General characteristics are described in Table 1 .
No significant association was found between PWV and any of the polymorphisms, either in unadjusted analyses (model 1) or adjusted analyses (models 2 and 3) ( Table 2 ). None of the tests for trend were significant (-800 G/A P ¼ 0.559, -509 C/T P ¼ 0.294, c10 P ¼ 0.977 or c25 P ¼ 0.282). Full adjustment did not alter the findings. The haplo- type-based analyses also showed no differences in PWV between the haplotypes ( Table 3) . The DC showed no association with any of the polymorphisms, except for a lower DC for subjects with the -509 TT in comparison to those with the CT genotype ( Table 2 ). No overall trends were shown for the -800 G/A polymorphism (P ¼ 0.320), the -509 C/ T (P ¼ 0.376), c10 (P ¼ 0.215) or c25 (P ¼ 0.866) in the unadjusted analyses. Further adjustment did not alter these results. Also the haplotype-based analyses showed no differences in DC between any of the haplotypes (Table 3) .
No association between PP and any of the genotypes was shown (Table 2 ). Also no trends were shown (-800 G/A P ¼ 0.895; -509 C/T P ¼ 0.549; c10 P ¼ 0.824 and c25 P ¼ 0.433). Further adjustment did not alter these results. Also the haplotype-based analyses showed no differences in PP between any of the haplotypes (Table 3) .
The gender-stratified analyses showed no results essentially different from the overall analyses (data not shown).
Discussion
We studied four well-known functional TGF-b1 polymorphisms (-800 G/A, -509 C/T, c10 and c25) in relation to arterial stiffness. None of the polymorphisms were consistently and significantly associated with either PWV, DC or PP in both genotype-and haplotype-based analyses.
To the best of our knowledge, there are no previous studies on these polymorphisms and their association with arterial stiffness.
Although the TGF-b polymorphisms may influence expression or activity of TGF-b, and this, in turn, may influence arterial stiffness, we did not find these polymorphisms to be associated with arterial stiffness. We consider the finding of a significant difference in the DC between subjects with the -509 CT and TT genotype no valid evidence for an association between the polymorphism and arterial stiffness, especially because this isolated finding was not supported by a corroborating trend or findings for PWV or PP. We hypothesize that any effects that these TGF-b polymorphisms might have on the vascular wall, do not lead to significant changes in arterial stiffness.
Our study is based on a large ongoing populationbased study in a relatively homogeneous population, as 98% of the participants in our study are Caucasian and are all living in the same area, a suburb of Rotterdam. We used both genotype-and haplotype-based analyses. The DC has a strong correlation with mean arterial pressure; a higher MAP in the artery especially stretches the collagen fibres in the arterial wall, making the arteries less distensible. Consequently, the analyses were also adjusted for mean arterial pressure. We adjusted all analyses for established risk factors. As atherosclerosis and arterial stiffness are associated, we additionally adjusted for atherosclerosis. 6 To interpret the findings correctly, several methodological aspects of the measures of arterial stiffness need to be discussed. First, pulse waves in the carotid artery and the femoral artery travel in opposite directions, whereas measurements of carotid-femoral PWV is based on the assumption that the pulse wave travels from the carotid artery to the femoral artery. In this way, measuring the distance between the carotid and the femoral artery lead to an overestimation of the distance between the sites of the pulse waves resulting in overestimation of the velocity of the pulse waves. However, variations in anatomy are limited and this error may be considered similar for all subjects examined, therefore we do not think it has seriously biased our results. Second, the distance between the carotid and the femoral artery may be overestimated in (especially obese) subjects when this distance is measured by tape; to avoid this error we adjusted the analyses for BMI. 9 Third, in computing the carotid DC, we used the brachial PP rather than the carotid PP. 9 Information on comparisons between the carotid and the brachial PP indicates that the carotid PP is lower than the brachial PP, but differences are relatively small. 33 Fourth, large topographic/anatomical differences exist in the structure and function of the arterial system. As a consequence, arterial stiffness cannot be assessed by a single measurement at any random site within the arterial system. In the Rotterdam Study, we use three diverse measures of arterial stiffness. We used PWV, as this is the most Abbreviations: DC, distensibility coefficient; HR, heart rate; MAP, mean arterial pressure; PWV, pulse wave velocity; TGF-b transforming growth factor b.
Measurements are depicted as: mean (95% confidence interval). Adjusted for age and sex (and for PWV and DC also for MAP and HR).
generally accepted and robust measure of arterial stiffness in general. 34 As the local measure of the carotid DC may also be of prognostic importance and offer additional information, we also used the carotid DC as a measure of stiffness. 34 Additionally we used PP. This is not a direct measurement of stiffness, but it can be used as an additional noninvasive and readily obtainable indicator for arterial stiffness.
Furthermore some general remarks need to be made. The effects of genetic variation on a trait with a complex and multifactorial pathogenesis, such as arterial stiffness, are generally modest. Power estimates for all analyses in this study were generally o80%. Our negative findings, therefore, do not exclude the possibility that small effects were not detected, however, it is unlikely that large effects were missed. Further, data on measures of stiffness were not available for all subjects. However, missing information was primarily owing to logistic reasons, which is likely to be random and is unlikely to have introduced bias in our results. Furthermore, the cross-sectional design may limit the ability to infer a causal relationship between the TGF-b1 polymorphisms and arterial stiffness. Also, the generalizability of our findings to younger individuals or persons of other ethnicities remains uncertain, owing to the fact that our population consisted of (mostly) elderly Caucasion subjects. Furthermore, the advantage of the allele-based haplotype analysis is the increase in power in comparison with genotype-based analyses. However, the allele-based haplotype analyses offer no information on possible dominance or recessiveness. Also, the polymorphisms used in this study were selected based on potential functionality and literature. They were not selected as 'tagging' polymorphisms to cover all genetic variation in the TGF-b1 gene. Finally, the relation between the polymorphisms/haplotypes, arterial stiffness and plasma levels of TGF-b could not be investigated, because, unfortunately, no TGF-b levels were measured in the Rotterdam Study.
In conclusion: we found the TGF-b1 -800 G/A, À509 C/T, codon 10 Leu/Pro and codon 25 Arg/Pro polymorphisms not to be associated with arterial stiffness, either in genotype or haplotype-based analyses. However, we cannot exclude a small effect, which was not detected in our study. Additional studies are needed for confirmation and to further elucidate the effects of these potentially functional TGF-b1 polymorphisms on the vascular wall.
